… Bykerk has received consulting fees, speaking fees, and/or honoraria from Amgen, Wyeth,
Abbott, Schering-Plough, Roche, Bristol-Myers Squibb, and UCB (less than $10,000 each); …

Background Despite the importance of timely management of patients with inflammatory
arthritis (IA), delays exist in its diagnosis and treatment. Objective To perform a systematic …

Objective. Medication adherence in patients with rheumatoid arthritis (RA) is typically suboptimal.
Nonadherence has been associated with symptom worsening and increased disability. …

CD4 + T cells are central mediators of autoimmune pathology; however, defining their key
effector functions in specific autoimmune diseases remains challenging. Pathogenic CD4 + T …

Objective. Tumour necrosis factor α inhibitors (TNFis) are widely used in RA patients who
undergo surgery, and optimal perioperative management must balance the risk of infection …

To define the cell populations that drive joint inflammation in rheumatoid arthritis (RA), we
applied single-cell RNA sequencing (scRNA-seq), mass cytometry, bulk RNA sequencing (…

Objective. To compare the relative efficacy and tolerability of amitriptyline, cyclobenzaprine,
and placebo in the treatment of fibromyalgia, and to identify predictors of response to …

Fibroblasts regulate tissue homeostasis, coordinate inflammatory responses, and mediate
tissue damage. In rheumatoid arthritis (RA), synovial fibroblasts maintain chronic inflammation …

Objective The American College of Rheumatology and the European League Against
Rheumatism have developed new classification criteria for rheumatoid arthritis (RA). The aim of …

Objective. The Canadian Rheumatology Association (CRA) has developed recommendations
for the pharmacological management of rheumatoid arthritis (RA) with traditional and …